Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epidemiology and Biomarker Study in Alzheimer's Disease
Sponsor: Eli Lilly and Company
Summary
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Official title: A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
Key Details
Gender
All
Age Range
55 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
3400
Start Date
2025-08-25
Completion Date
2033-07
Last Updated
2026-02-10
Healthy Volunteers
Yes
Conditions
Interventions
P-tau217 Test
A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
Locations (3)
Care Access - Houston
Houston, Texas, United States
The University of Tokyo Hospital
Bunkyō City, Japan
Souseikai Sumida Hospital
Tokyo, Japan